Suppression of glioblastoma by a drug cocktail inducing tumor cells toward a neuronal fate
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA432933 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR6671431_1.fastq.gz | Fastqsanger.gz | |||
| SRR6671431_2.fastq.gz | Fastqsanger.gz | |||
| SRR6671432_1.fastq.gz | Fastqsanger.gz | |||
| SRR6671432_2.fastq.gz | Fastqsanger.gz | |||
| SRR6671433_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 8 |
Similar Datasets
Project description:Glioblastoma (GBM), the most common and aggressive malignant tumor in adult brain, is a notoriously fatal tumor. For many years, surgical resection and postoperative radiotherapy had been used for the treatment of GBM, which resulted in a poor median survival of about 12 months. Currently, Temozolomide (TMZ) as a clinically meaningful chemotherapy drug has become the standard first-line treatment for GBM, but with an increase of the median survival for about only 2.5 months. In this study, encouraged by previous findings that human astrocytes could be converted into neuronal cells with small molecules and that human GBM cells could be induced into neuronal like cells by transcription factors, we intended to test whether GBM cells could be induced into neuronal like cells by a cocktail of approved drugs and whether this drug cocktail help to suppress GBM in patient derived xenograft (PDX). Here we screened and identified TMZ, Tranilast, and Fasudil, three approved clinical drugs (TTF), to induce GBM cells toward a neuronal fate. Both serum and serum-free cultured GBM cells exhibited neuronal morphology and expressed neuronal genes under TTF treatment. Malignant properties including uncontrolled proliferation and intensive invasion of GBM cells were also attenuated with TTF treatment. Most importantly, when administrated in PDX, TTF cocktail significantly suppressed GBM growth in vivo and prolonged the survival of tumor-bearing mice, as compared to TMZ alone. Our study indicated that using the approved drug cocktail to induce tumor cells toward a neuronal fate might be a clinically promising strategy for GBM treatment.
2019-03-12 | GSE110130 | GEO
Project description:ZFHX4 and CHD4 suppression independently shift tumor initiating cells out of a stem like state and toward a differentiated morphology. After gene suppression via transduction of a lentivirally mediated shRNA construct, RNA was extracted 3 and 5 days later and was hybridized on Affymetrix microarrays. Total RNA was extracted 3 and 5 days after shRNA transduction of 0308 TICs, for 3 (for CHD4) or 5 (ZFHX4) independent experiments. Complementary RNA synthesis and hybridization/scanning of U133 plus 2.0 microarrays using GeneChip products (Affymetrix) was done as described in the GeneChip manual.
2014-01-16 | E-GEOD-52363 | biostudies-arrayexpress
Project description:ZFHX4 and CHD4 suppression independently shift tumor initiating cells out of a stem like state and toward a differentiated morphology. After gene suppression via transduction of a lentivirally mediated shRNA construct, RNA was extracted 3 and 5 days later and was hybridized on Affymetrix microarrays.
2014-01-16 | GSE52363 | GEO
Project description:Cytotoxic T cells are typically expanded ex vivo for adoptive immunotherapy by culture with IL-2. This culture period leads to a differentiated phenotype and acquisition of effector function, as well as a loss of in vivo proliferative capability and anti-tumor efficacy. Here, we report antigen-specific and polyclonal expansion of cytotoxic T cells in a cocktail of cytokines and small molecules that leads to a memory-like phenotype in mouse and human cells even during extended culture, leading to enhanced in vivo expansion and tumor control. OT-I CD8 T cells were cultured for 14 days in either IL-2 or a cocktail of memory inducing small molecules and cytokines (IL-7, IL-21, 2-deoxyglucose and TWS119). Populations were sorted, IL-2 cells were CD44+CD62L-, cocktail cells were sorted into CD44+CD62L-, CD44+CD62L+ and CD44lowCD62L+ populations, and naive OT-I cells were CD44-CD62L+. Total RNA was extracted from each population and prepared for sequencing as three technical replicates.
2014-08-12 | E-GEOD-54877 | biostudies-arrayexpress
Project description:The affection of Sirt1 on astrocyte is not well understanded. Here we studied the change of RNA expression profile after Sirt1 knockout in primary astrocyte after stimulating with A1 astrocyte inducing cocktails. To analyze the change of RNA expression profile after Sirt1 knockout in astrocytes, we built Sirt1 knockout and control astrocytes using crispr technique, and analyzed RNA expression profiles of Sirt1 KO and control astrocytes after treating with cocktail (C1q, IL-1α, TNF-α) by using microarray.
2022-10-17 | GSE212924 | GEO
Project description:Gut microbiome of housefly treated with bacteria cocktail or phage cocktail Raw sequence reads
| PRJNA971253 | ENA
Project description:Inducing tumor cell differentiation is a potential strategy for treating malignant cancers, including glioma. Here we perform a genome-scale CRISPR activation screen and identify that G Protein Subunit Alpha O1 (GNAO1) as a critical regulator of glioma cell differentiation. GNAO1 overexpression in combination with a small molecular inhibitor cocktail, including CHIR99021, SB431542, RepSox, and Y27632, markedly promotes neuronal differentiation of glioblastoma cells. GNAO1 is high expressed in normal neuronal tissues but low expressed in gliomas. High expression of GNAO1 is correlated with a better prognosis. GNAO1 overexpression decreases cell proliferation, cell migration, and orthotopic GBM tumor xenograft growth. GNAO1 overexpression activates neuronal differentiation pathways by down-regulation of transcript factor HES1, a key mediator of neuronal differentiation. GNAO1 recruits TRIM21 and increases TRIM21-mediated ubiquitination and degradation of CREB, leading to decreased p300-mediated H3K27ac levels of HES1 promoter and HES1 downregulation. In addition, GNAO1 mRNA stability is regulated by METTL3-regulated N6-methyladenosine (m6A). Overexpression of GNAO1 enhances glioblastoma response to Temozolomide (TMZ) and extends the survivals of animals bearing orthotopic GBM xenograft tumors. Our finding suggests that inducing neuronal differentiation of glioblastoma cells by engineering GNAO1 overexpression is a potential therapy strategy, which not only reduces tumor cell proliferation but also enhances tumor cell response to chemotherapy.
2026-01-07 | GSE234341 | GEO
Project description:Astrocyte-driven suppression of tumor-specific T-cell immunity in glioblastoma
| PRJNA1032462 | ENA
Project description:Glioblastoma is a highly malignant and incurable brain tumor characterized by intrinsic and adaptive resistance to immunotherapies. However, how glioma cells induce tumor immunosuppression and escape immunosurveillance remains poorly understood. Here, we find upregulation of cancer-intrinsic Chitinase-3-like-1 (CHI3L1) signaling modulating an immunosuppressive microenvironment by reprogramming tumor-associated macrophages (TAMs). Mechanistically, CHI3L1 binding with Galectin-3 (Gal3) selectively promotes TAM migration and infiltration with a protumor M2-like but not an antitumor M1-like phenotype in vitro and in vivo, governed by a transcriptional program of NFκB/CEBPβ in the CHI3L1/Gal3-PI3K/AKT/mTOR axis. Conversely, Galectin-3-binding protein (Gal3BP) negatively regulates this process by competing with Gal3 to bind CHI3L1. Administration of a Gal3BP mimetic peptide in a syngeneic glioblastoma mouse model reverses immune suppression and attenuates tumor progression. These results shed light on the role of CHI3L1 protein complexes in immune evasion by glioblastoma and as a potential immunotherapeutic target for this devastating disease.
2021-05-11 | GSE174177 | GEO
Project description:Glioblastoma (GBM) is the most common and aggressive malignant tumor in adult brain. Even with the current standard therapy including surgical resection followed by postoperative radiotherapy and chemotherapy with temozolomide (Temo), GBM patients still have a poor median survival. Reprogramming of tumor cells into non-malignant cells might be a promising therapeutic strategy for malignant tumors, including GBM. Based on previous studies using small molecules to reprogram astrocytes into neuronal cells, here we further identified a FTT cocktail of three commonly used drugs (Fasudil, Tranilast, and Temo) to reprogram patient-derived GBM cells, either cultured in serum containing or serum-free medium, into neuronal like cells. FTT-treated GBM cells displayed a neuronal like morphology, expressed neuronal genes, exhibited neuronal electrophysiological properties, and showed attenuated malignancy. More importantly, FTT cocktail more significantly suppressed tumor growth and prolonged survival in GBM patient derived xenograft than Temo alone. Our study provided preclinical evidence that the neuronal reprogramming drug cocktail might be a promising strategy to improve the existing treatment for GBM.
| S-EPMC6401026 | biostudies-literature